Is Obesity Genetic or Environmental? YES!
Vocabulary-GWAS – A Genome-Wide Association Study – a research method used to identify genetic variations (like single nucleotide polymorphisms or SNPs) associated with a specific disease or trait. It involves comparing the genomes of individuals with the disease or trait to those without it to find variations that occur more frequently in the affected group. SNP […]
Predicting and Preventing Alzheimer’s Disease
This week I published an essay in the journal Science on the exciting potential to get ahead of Alzheimer’s disease. That was written a few weeks ago and several important and highly relevant reports have since been published. I’ve incorporated them in this updated version of how we can move forward to prevent this dreaded […]
How do GLP-1 drugs work? This book answers all your questions
Dr Alexandra Sowa, author of ‘The Ozempic Revolution’, talks about how GLP-1s are changing the way America eats, dresses and shops.
How Making GLP-1s Available Over the Counter Can Unlock Their Full Potential
When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the first glucagon-like peptide-1 (GLP-1) agonist to treat Type 2 diabetes. But this new drug class had the potential to treat a host of other problems. GLP-1 agonists mimic the body’s intrinsic GLP-1, a hormone that stimulates insulin release, […]
GLP‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Abstract Aims To assess if there is a difference in the oncogenic risk between GLP-1 RA and comparators in randomized controlled trials. Materials and Methods A meta-analysis of randomized controlled trials comparing GLP-1RA to any comparators for diabetes and/or obesity, lasting at least 52 weeks. The endpoints included the incidence of overall cancers and single malignancies. […]
Leading health organizations release guidance on nutrition support for GLP-1 obesity therapies
Four leading organizations in lifestyle medicine, obesity medicine, and nutrition-the American College of Lifestyle Medicine (ACLM), the American Society for Nutrition (ASN), the Obesity Medicine Association (OMA), and The Obesity Society (TOS)-have jointly released a clinical advisory titled “Nutritional Priorities to Support GLP-1 Therapy for Obesity.”
Food and fitness make or break success on weight loss meds, report finds – ABC News
Food and fitness make or break success on weight loss meds, report finds ABC News Medical groups release guidance on nutritional support for patients using GLP-1s Healio Helping Patients Navigate GLP-1 Therapy: Practical Strategies for Pharmacists Pharmacy Times Nutritional Priorities to Support GLP-1 Therapy for Obesity | Newswise Newswise GLP-1 users lack vital nutrients, GNC reports NutraIngredients-USA.com
Intestinal L-cell mechanoreception regulates hepatic lipid metabolism through GLP-1
Science Advances, Volume 11, Issue 22, May 2025.
FDA Accepts Application for Oral Version of Wegovy
The US Food and Drug Administration (FDA) recently accepted a new drug application for oral semaglutide. If approved, it would be the first oral glucagon-like peptide-1 (GLP-1) receptor agonist authorized for long-term weight management. The 25-mg semaglutide pill would be marketed as Wegovy, the same name used for Novo Nordisk’s FDA-approved 2.4-mg semaglutide injection.
For diabetics, weight-loss drugs might lessen cancer risk, study finds
Excess body weight can raise the risk of certain cancers. So researchers have been wondering: Might blockbuster weight-loss drugs like Wegovy, Ozempic and Zepbound also play a role in cancer prevention? Now, a study being presented at a major cancer research conference study in Chicago suggests they could. The study found a slightly lower risk […]